Compare Enact Holdings Inc (ACT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs GeneDx Holdings Corp — how do they compare? Enact Holdings Inc trades at $49.39 (market cap $6.75B), while GeneDx Holdings Corp trades at $82.69 (market cap $2.44B). The key difference: Enact Holdings Inc is far larger — about 2.8× GeneDx Holdings Corp's market cap, and Enact Holdings Inc pays a 1.95% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ACT | WGS | |
|---|---|---|
Market Cap | $6.75B | $2.44B |
Sector | Technology | Technology |
52-Week High | $49.12 | $167.51 |
52-Week Low | $34.93 | $34.51 |
Enterprise Value | $7.05B | $2.48B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.47, up 2.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.5% and ROE of 12.9%, supported by recent earnings beats. Revenue growth is modest, and the company maintains a consistent dividend policy. Analyst consensus is a $49.00 price target with a mix of buy and hold ratings.
Outlook is stable with solid fundamentals, but high valuation multiples and overbought technicals suggest limited near-term upside. Risks include reliance on earnings consistency and market sentiment shifts. The stock offers value through dividends and profitability, yet investors should weigh current levels against growth prospects.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
